Interaction Checker

Prescribing Resources

We have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19.

These resources are freely available and the Liverpool Drug Interactions Group would like to encourage the dissemination (with an appropriate acknowledgement) of this drug-drug interaction information for non-commercial use. If referencing these Prescribing Resources, it is important to include the publication date since these resources are updated as new data come to light. Please cite as: [Prescribing Resource Title], [PDF Publication Date], University of Liverpool, available from www.covid19-druginteractions.org, [accession date].

Evaluating the interaction risk of COVID-19 therapies.

UPDATED - Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.

This document explains how we have evaluated the drug-drug interaction risk of the COVID-19 therapies (licensed and under clinical investigation) and gives details of their metabolism, interaction potential and cardiac effects.

Click here to view PDF.

Updated 17 January 2022

"Treatment Selector" for Key COVID-19 Therapies

NEW - detailed recommendations for key COVID-19 therapies (including Paxlovid).

Details of the nature of drug interactions with key COVID-19 therapies and many comedication classes are given in this PDF.

Click here to view PDF.

Updated 17 January 2022

At-a-glance summary of interactions with COVID-19 antiviral therapies.

UPDATED – Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.

A summary of interactions with COVID-19 antiviral therapies (licensed or under clinical investigation) and over 500 comedications are given in this PDF.

Click here to view PDF.

Updated 17 January 2022

At-a-glance summary of interactions with COVID-19 host-directed therapies.

UPDATED – Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added

A summary of interactions with COVID-19 host-directed therapies (licensed or under clinical investigation) and over 500 comedications are given in this PDF.

Click here to view PDF.

Updated 17 January 2022

At-a-glance summary of interactions with COVID-19 adjunct therapies.

UPDATED – Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.

A summary of interactions with COVID-19 adjunct therapies and over 500 comedications are given in this PDF.

Click here to view PDF.

Updated 17 January 2022

Administration in cases of swallowing difficulties.

UPDATED - Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.

Advice for administering COVID-19 therapies (licensed or under clinical investigation) to patients who cannot swallow is given in this PDF.

Click here to view PDF.

Updated 17 January 2022

Dose recommendations for patients with renal impairment

UPDATED - Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.

Details of dose modifications for COVID-19 therapies (licensed or under clinical investigation) which may be required for patients with renal impairment are given in this PDF.

Click here to view PDF.

Updated 17 January 2022

Dose recommendations for patients with hepatic impairment

UPDATED - Nirmatrelvir/ritonavir (Paxlovid) and tixagevimab/cilgavimab (Evusheld) added.

Details of dose modifications for COVID-19 therapies (licensed or under clinical investigation) which may be required for patients with hepatic impairment are given in this PDF.

Click here to view PDF.

Updated 17 January 2022

Academic Sponsors / Collaborators
Editorial Sponsors / Research Funders